

Bilaga 7 till SBU-rapport

Behandling av armfraktur hos vuxna, rapport 262 (2017)

Bilaga 7 Studier som ligger till grund for resultat och slutsatser (hälsoekonomiska studier)/ Studies used for results and conclusions (health economic evaluations).

Cost-utility analyses of surgical treatments in patients with distal radius fractures

Author	Study design	Intervention	Incremental cost (95	Incremental	ICER	Study quality and
Year	Population	VS	% CI)	Effect (95 % CI)		transferability*
Reference	Setting	control				Further information
Country	Perspective					Comments
Tubeuf et	RCT-based	Volar	NHS PSS perspective:	NHS PSS perspective:	NHS PSS perspective:	Moderate quality, high
al.	CUA,	locking plate	GBP 752 (539-921)	0.014 QALYs (0.002-	GBP 54 218 per QALY	transferability.
2015	Sub group	(n=230)	Societal perspective:	0.025)		
UK	analysis of	versus	GBP 629 (412-845)		Societal perspective: GBP	Based on the DRAFFT
{Tubeuf,	patients >50	percutaneous		Societal perspective:	35 323 per QALY*	Trial (Costa 2014, Costa
2015 #95}	years	Kirschner	Costs reported in GBP	0.018 QALYs (0.007-		2015)
	(imputed), 12	wires	(£) year 2012.	0.029)*		
	month time	(n=230)				
	horizon, NHS					
	and Personal					
	Social Services					
	perspective as					

well as societa			
perspective			

CA = Cost analysis; CBA = Cost-benefit analysis; CEA = Cost-effectiveness analysis; CUA = Cost-utility analysis; GBP = British pound; ICER = Incremental cost-effectiveness ratio; USD = United States Dollar, * Societal perspective was used as a sensitivity analysis and included a changed incremental effect.



Bilaga 7 till SBU-rapport

3 (4)

Behandling av armfraktur hos vuxna, rapport 262 (2017)

Cost-utility analyses comparing surgical with non-surgical (conservative) treatment in patients with proximal humeral fractures

Author	Study design	Intervention	Incremental cost	Incremental	ICER	Study quality and
Year	Population	vs	(95% CI)	Effect (95%		transferability*
Reference	Setting	control		CI)		Further information
Country	Perspective					Comments
Corbacho et	RCT-based CUA	Surgical (n=54,	Total costs (GBP	-0.0101 QALYs	Dominated,	Moderate quality, high
al.	Proximal humeral	the surgeons	2012):	(-0.13- 0.11)	Probability cost-	transferability,
2016 UK	fractures, 24	could choose the	1758 (1126-2389)		effective at WTP of	
{Corbacho,	months time	type of surgery)			£30,000 per QALY:	Complete data (both costs
2016 #97}	horizon, UK NHS	versus non-	Costs reported in		0.23	and utilities) was only
	and Personal	surgical	GBP (£) year 2012			available for 40% of the
	Social Services	treatment (n=46,				patients included in the trial
	perspective	initially the use				
	Mean age 66	of a sling)				
	years					
Fjalestad et	RCT-based CUA	Plate fixation	Health care	0.009 QALYs (-	Health care	Moderate quality
al.	Proximal humeral	(n=25) versus	perspective EURO:	0.025-0.042)	perspective:	High transferability
2010	fractures,	Conservative	-597 (-5,291-3,777)		Dominating	
Norway	60+ years old, 12	treatment				
{Fjalestad,	month time	(n=25)	Societal perspective		Societal perspective:	
2010 #94}	horizon,		EURO:		EURO 230.556	

	Norwegian societal perspective		2,075 (-1,244- 9,436) Costs reported in Euro (€) year 2005			
Nwachukwu et al. US 2016 {Nwachukw u, 2016 #98}	Model-based CUA, Complex proximal humerus, cohort of 70-year old patients, life time horizon, payer and health care perspective	Shoulder hemiarthroplast y (HA), and Reverse shoulder arthroplasty (RSA) vs. non- surgical care	Health care perspective (life time costs): HA vs non-surgical care: USD 63,600 RTSA vs non-surgical care: USD 92,200 Costs reported in US dollars (\$) year 2013	HA vs non- surgical care: 1.73 QALYs RTSA vs non- surgical care: 2.27 QALYs	Health care perspective (life time costs): HA vs non-surgical care: USD 36,700 per QALY RTSA vs non-surgical care: USD 40,600 per QALY RTSA vs HA: USD 53,000 per QALY	Moderate quality, low transferability. Assumed that the non-operative care had no cost. Unclear what the different perspectives include. Based on the results of several different RCTs

^{*} Study quality is a combined assessment of the quality of the study from a clinical as well as an economic perspective [ref till engelska versionen av granskningsmallarna]. CA = Cost analysis; CBA = Cost-benefit analysis; CEA = Cost-effectiveness analysis; CUA = Cost-utility analysis; GBP = British pound; ICER = Incremental cost-effectiveness ratio; USD = United States Dollars